OCM
HRTX icon

Orchard Capital Management’s Heron Therapeutics HRTX Stock Holding History

Orchard Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-680,432
Closed -$544K – 50
2026
Q1 		$544K Hold
680,432
– – 0.57% 31
2025
Q4 		$885K Buy
680,432
+3,142
+0.5% +$3.88K 0.77% 28
2025
Q3 		$853K Buy
677,290
+17,357
+3% +$27.5K 0.74% 29
2025
Q2 		$1.37M Sell
659,933
-771,825
-54% -$1.58M 1.51% 24
2025
Q1 		$3.15M Sell
1,431,758
-444,702
-24% -$863K 2.15% 23
2024
Q4 		$2.84M Sell
1,876,460
-103,738
-5% -$168K 1.12% 29
2024
Q3 		$3.95M Sell
1,980,198
-263,228
-12% -$629K 1.36% 30
2024
Q2 		$7.85M Sell
2,243,426
-28,457
-1% -$87.4K 2.37% 21
2024
Q1 		$6.29M Buy
2,271,883
+28,457
+1% +$71.5K 1.85% 31
2023
Q4 		$3.81M Buy
2,243,426
+100,603
+5% +$111K 1.19% 34
2023
Q3 		$2.21M Buy
2,142,823
+751,743
+54% +$1.07M 0.82% 36
2023
Q2 		$1.61M Hold
1,391,080
– – 0.54% 37
2023
Q1 		$2.1M Hold
1,391,080
– – 0.7% 36
2022
Q4 		$3.48M Hold
1,391,080
– – 1.17% 35
2022
Q3 		$5.87M Buy
1,391,080
+365,056
+36% +$1.43M 2.2% 25
2022
Q2 		$2.85M Buy
1,026,024
+59,100
+6% +$237K 0.89% 34
2022
Q1 		$5.53M Buy
966,924
+600,920
+164% +$4.4M 1.57% 30
2021
Q4 		$3.34M Buy
366,004
+7,100
+2% +$72.5K 0.98% 32
2021
Q3 		$3.84M Hold
358,904
– – 1.15% 31
2021
Q2 		$5.57M Buy
+358,904
New +$5.71M 1.61% 31

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Orchard Capital Management's HRTX Position: Q2 2026 in Review

Orchard Capital Management sold out of Heron Therapeutics (HRTX) in Q2 2026, closing a stake of 680,432 shares — an estimated $544K sold.

Orchard Capital Management first reported a position in HRTX in Q2 2021 and held it in 20 quarters. The position peaked at $7.85M in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Orchard Capital Management reported no remaining Heron Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Orchard Capital Management sold 680,432 Heron Therapeutics shares in Q2 2026, an estimated $544K.
  • Orchard Capital Management first reported a position in Heron Therapeutics in Q2 2021 and held it in 20 quarters.
  • Orchard Capital Management's Heron Therapeutics position peaked at $7.85M in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Orchard Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.